Lebensburger, Jeffrey D.
Cutter, Gary R.
Howard, Thomas H.
Muntner, Paul
Feig, Daniel I.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (5K23HL127100)
American Society of Hematology (Scholar Award)
Article History
Received: 20 December 2016
Revised: 9 March 2017
Accepted: 10 March 2017
First Online: 5 April 2017
Compliance with ethical standards
: The Institutional Review Board at the University of Alabama at Birmingham (UAB) approved this study of the evaluation of risk factors for the progression to sickle cell nephropathy and written consent and assent was obtained from every parent and child enrolled.
: JL wrote the first draft or the manuscript. All five authors participated in editing the drafts of this manuscript. PM, GC, and DF assisted JL in the design and analysis of the manuscript and serve as primary mentors for JL’s K23 award and TH serves as an advisory panel member.
: GRC discloses the following: (1) participation in Data and Safety Monitoring Boards, as follows: Apotek, Biogen-Idec, Cleveland Clinic (Vivus), Glaxo Smith Klein Pharmaceuticals, Gilead Pharmaceuticals, Modigenetech/Prolor, Merck/Ono Pharmaceuticals, Merck, Merck/Pfizer, Neuren, Sanofi-Aventis, Teva, Washington University, NHLBI (Protocol Review Committee), NINDS, NICHD (OPRU oversight committee); (2) participation on Consulting or Advisory Boards, as follows: Consortium of MS Centers (grant), D3 (Drug Discovery and Development), Genzyme, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Novartis, Opexa Therapeutics, Receptos, Roche, EMD Serono, Teva pharmaceuticals, Transparency Life Sciences. GRC is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc. a private consulting company located in Birmingham, Alabama.